Literature DB >> 21135179

Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus.

Sandrine Lemaire1, Paul M Tulkens, Françoise Van Bambeke.   

Abstract

In contrast to currently marketed fluoroquinolones, which are zwitterionic, delafloxacin is an investigational fluoroquinolone with an anionic character that is highly active against Gram-positive bacteria. We have examined the effect of acidic pH on its accumulation in Staphylococcus aureus and in human THP-1 cells, in parallel with its activity against extracellular and intracellular S. aureus. Moxifloxacin was used as a comparator. Delafloxacin showed MICs 3 to 5 log(2) dilutions lower than those of moxifloxacin for a collection of 35 strains with relevant resistance mechanisms and also proved to be 10-fold more potent against intracellular S. aureus ATCC 25923. In medium at pH 5.5, this difference was further enhanced, with the MIC decreasing by 5 log(2) dilutions. In infected cells incubated in acidic medium, the relative potency was 10-fold higher than that at neutral pH and the maximal relative efficacy reached a bactericidal effect at 24 h. These results can be explained by a 10-fold increase in delafloxacin accumulation in both bacteria and cells at acidic pH, making delafloxacin one of the most efficient drugs tested in this model. Opposite effects were seen for moxifloxacin with respect to both activity and accumulation. As reported for zwitterionic fluoroquinolones, delafloxacin was found associated with the soluble fraction in homogenates of eukaryotic cells. Taken together, these properties may confer to delafloxacin an advantage for the eradication of S. aureus in acidic environments, including intracellular infections.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21135179      PMCID: PMC3028753          DOI: 10.1128/AAC.01201-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  42 in total

1.  In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.

Authors:  Laurel S Almer; Jennifer B Hoffrage; Erika L Keller; Robert K Flamm; Virginia D Shortridge
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

2.  Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages.

Authors:  Sandrine Lemaire; Françoise Van Bambeke; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

3.  Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.

Authors:  L E Bermudez; C B Inderlied; P Kolonoski; M Petrofsky; P Aralar; M Wu; L S Young
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

4.  Disposition and intracellular levels of moxifloxacin in human THP-1 monocytes in unstimulated and stimulated conditions.

Authors:  Iris H Hall; Ute E Schwab; E Stacy Ward; Timothy Ives
Journal:  Int J Antimicrob Agents       Date:  2003-12       Impact factor: 5.283

5.  Impairment of growth of Listeria monocytogenes in THP-1 macrophages by granulocyte macrophage colony-stimulating factor: release of tumor necrosis factor-alpha and nitric oxide.

Authors:  Stéphane Carryn; Sébastien Van de Velde; Françoise Van Bambeke; Marie-Paule Mingeot-Leclercq; Paul M Tulkens
Journal:  J Infect Dis       Date:  2004-05-12       Impact factor: 5.226

6.  In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.

Authors:  Angela M Nilius; Linus L Shen; Dena Hensey-Rudloff; Laurel S Almer; Jill M Beyer; Darlene J Balli; Yingna Cai; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

7.  Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo.

Authors:  Nicolas Veziris; Chantal Truffot-Pernot; Alexandra Aubry; Vincent Jarlier; Nacer Lounis
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

8.  Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus.

Authors:  Cristina Seral; Stéphane Carryn; Paul M Tulkens; Françoise Van Bambeke
Journal:  J Antimicrob Chemother       Date:  2003-04-14       Impact factor: 5.790

9.  Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages.

Authors:  Cristina Seral; Françoise Van Bambeke; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

10.  Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations.

Authors:  Stéphane Carryn; Françoise Van Bambeke; Marie-Paule Mingeot-Leclercq; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

View more
  51 in total

Review 1.  Development of novel antibacterial drugs to combat multiple resistant organisms.

Authors:  Matteo Bassetti; Elda Righi
Journal:  Langenbecks Arch Surg       Date:  2015-02-11       Impact factor: 3.445

Review 2.  Antibiotics in the clinical pipeline at the end of 2015.

Authors:  Mark S Butler; Mark At Blaskovich; Matthew A Cooper
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

Review 3.  [New antibiotics prior to approval: is this the end of the innovative stagnation?].

Authors:  J R Bogner
Journal:  Internist (Berl)       Date:  2014-12       Impact factor: 0.743

4.  Recent Advances in the Rational Design and Optimization of Antibacterial Agents.

Authors:  Jesse A Jones; Kristopher G Virga; Giuseppe Gumina; Kirk E Hevener
Journal:  Medchemcomm       Date:  2016-07-07       Impact factor: 3.597

5.  BaxdelaTM (Delafloxacin): A Novel Fluoroquinolone for the Treatment of Acute Bacterial Skin and Skin Structure Infections.

Authors:  Alexandra Adler; Saira Chaudhry; Tamara Goldberg
Journal:  P T       Date:  2018-11

Review 6.  Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria.

Authors:  Neelam Taneja; Harsimran Kaur
Journal:  Microbiol Insights       Date:  2016-03-20

Review 7.  The evolving role of chemical synthesis in antibacterial drug discovery.

Authors:  Peter M Wright; Ian B Seiple; Andrew G Myers
Journal:  Angew Chem Int Ed Engl       Date:  2014-07-02       Impact factor: 15.336

8.  In Vitro Activity of Delafloxacin against Clinical Neisseria gonorrhoeae Isolates and Selection of Gonococcal Delafloxacin Resistance.

Authors:  Olusegun O Soge; Stephen J Salipante; David No; Erin Duffy; Marilyn C Roberts
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

9.  In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Authors:  Robert K Flamm; Paul R Rhomberg; Michael D Huband; David J Farrell
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

10.  Pharmacodynamic evaluation of the intracellular activity of antibiotics towards Pseudomonas aeruginosa PAO1 in a model of THP-1 human monocytes.

Authors:  Julien M Buyck; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.